386 related articles for article (PubMed ID: 25940428)
1. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
; Hollestelle A; van der Baan FH; Berchuck A; Johnatty SE; Aben KK; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Apicella C; Arndt V; Arnold N; Arun BK; Arver B; Ashworth A; ; Baglietto L; Balleine R; Bandera EV; Barrowdale D; Bean YT; Beckmann L; Beckmann MW; Benitez J; Berger A; Berger R; Beuselinck B; Bisogna M; Bjorge L; Blomqvist C; Bogdanova NV; Bojesen A; Bojesen SE; Bolla MK; Bonanni B; Brand JS; Brauch H; ; Brenner H; Brinton L; Brooks-Wilson A; Bruinsma F; Brunet J; Brüning T; Budzilowska A; Bunker CH; Burwinkel B; Butzow R; Buys SS; Caligo MA; Campbell I; Carter J; Chang-Claude J; Chanock SJ; Claes KBM; Collée JM; Cook LS; Couch FJ; Cox A; Cramer D; Cross SS; Cunningham JM; Cybulski C; Czene K; Damiola F; Dansonka-Mieszkowska A; Darabi H; de la Hoya M; deFazio A; Dennis J; Devilee P; Dicks EM; Diez O; Doherty JA; Domchek SM; Dorfling CM; Dörk T; Silva IDS; du Bois A; Dumont M; Dunning AM; Duran M; Easton DF; Eccles D; Edwards RP; Ehrencrona H; Ejlertsen B; Ekici AB; Ellis SD; ; Engel C; Eriksson M; Fasching PA; Feliubadalo L; Figueroa J; Flesch-Janys D; Fletcher O; Fontaine A; Fortuzzi S; Fostira F; Fridley BL; Friebel T; Friedman E; Friel G; Frost D; Garber J; García-Closas M; Gayther SA; ; ; Gentry-Maharaj A; Gerdes AM; Giles GG; Glasspool R; Glendon G; Godwin AK; Goodman MT; Gore M; Greene MH; Grip M; Gronwald J; Gschwantler Kaulich D; Guénel P; Guzman SR; Haeberle L; Haiman CA; Hall P; Halverson SL; Hamann U; Hansen TVO; Harter P; Hartikainen JM; Healey S; ; Hein A; Heitz F; Henderson BE; Herzog J; T Hildebrandt MA; Høgdall CK; Høgdall E; Hogervorst FBL; Hopper JL; Humphreys K; Huzarski T; Imyanitov EN; Isaacs C; Jakubowska A; Janavicius R; Jaworska K; Jensen A; Jensen UB; Johnson N; Jukkola-Vuorinen A; Kabisch M; Karlan BY; Kataja V; Kauff N; ; Kelemen LE; Kerin MJ; Kiemeney LA; Kjaer SK; Knight JA; Knol-Bout JP; Konstantopoulou I; Kosma VM; Krakstad C; Kristensen V; Kuchenbaecker KB; Kupryjanczyk J; Laitman Y; Lambrechts D; Lambrechts S; Larson MC; Lasa A; Laurent-Puig P; Lazaro C; Le ND; Le Marchand L; Leminen A; Lester J; Levine DA; Li J; Liang D; Lindblom A; Lindor N; Lissowska J; Long J; Lu KH; Lubinski J; Lundvall L; Lurie G; Mai PL; Mannermaa A; Margolin S; Mariette F; Marme F; Martens JWM; Massuger LFAG; Maugard C; Mazoyer S; McGuffog L; McGuire V; McLean C; McNeish I; Meindl A; Menegaux F; Menéndez P; Menkiszak J; Menon U; Mensenkamp AR; Miller N; Milne RL; Modugno F; Montagna M; Moysich KB; Müller H; Mulligan AM; Muranen TA; Narod SA; Nathanson KL; Ness RB; Neuhausen SL; Nevanlinna H; Neven P; Nielsen FC; Nielsen SF; Nordestgaard BG; Nussbaum RL; Odunsi K; Offit K; Olah E; Olopade OI; Olson JE; Olson SH; Oosterwijk JC; Orlow I; Orr N; Orsulic S; Osorio A; Ottini L; Paul J; Pearce CL; Pedersen IS; Peissel B; Pejovic T; Pelttari LM; Perkins J; Permuth-Wey J; Peterlongo P; Peto J; Phelan CM; Phillips KA; Piedmonte M; Pike MC; Platte R; Plisiecka-Halasa J; Poole EM; Poppe B; Pylkäs K; Radice P; Ramus SJ; Rebbeck TR; Reed MWR; Rennert G; Risch HA; Robson M; Rodriguez GC; Romero A; Rossing MA; Rothstein JH; Rudolph A; Runnebaum I; Salani R; Salvesen HB; Sawyer EJ; Schildkraut JM; Schmidt MK; Schmutzler RK; Schneeweiss A; Schoemaker MJ; Schrauder MG; Schumacher F; Schwaab I; Scuvera G; Sellers TA; Severi G; Seynaeve CM; Shah M; Shrubsole M; Siddiqui N; Sieh W; Simard J; Singer CF; Sinilnikova OM; Smeets D; Sohn C; Soller M; Song H; Soucy P; Southey MC; Stegmaier C; Stoppa-Lyonnet D; Sucheston L; ; Swerdlow A; Tangen IL; Tea MK; Teixeira MR; Terry KL; Terry MB; Thomassen M; Thompson PJ; Tihomirova L; Tischkowitz M; Toland AE; Tollenaar RAEM; Tomlinson I; Torres D; Truong T; Tsimiklis H; Tung N; Tworoger SS; Tyrer JP; Vachon CM; Van 't Veer LJ; van Altena AM; Van Asperen CJ; van den Berg D; van den Ouweland AMW; van Doorn HC; Van Nieuwenhuysen E; van Rensburg EJ; Vergote I; Verhoef S; Vierkant RA; Vijai J; Vitonis AF; von Wachenfeldt A; Walsh C; Wang Q; Wang-Gohrke S; Wappenschmidt B; Weischer M; Weitzel JN; Weltens C; Wentzensen N; Whittemore AS; Wilkens LR; Winqvist R; Wu AH; Wu X; Yang HP; Zaffaroni D; Pilar Zamora M; Zheng W; Ziogas A; Chenevix-Trench G; Pharoah PDP; Rookus MA; Hooning MJ; Goode EL
Gynecol Oncol; 2016 May; 141(2):386-401. PubMed ID: 25940428
[TBL] [Abstract][Full Text] [Related]
2. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD; Palmieri RT; Ramus SJ; Gayther SA; Andrulis IL; Anton-Culver H; Antonenkova N; Antoniou AC; Goldgar D; ; Beattie MS; Beckmann MW; Birrer MJ; Bogdanova N; Bolton KL; Brewster W; Brooks-Wilson A; Brown R; Butzow R; Caldes T; Caligo MA; Campbell I; Chang-Claude J; Chen YA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Despierre E; Doherty JA; Dörk T; Dürst M; Eccles DM; Ekici AB; Easton D; ; Fasching PA; de Fazio A; Fenstermacher DA; Flanagan JM; Fridley BL; Friedman E; Gao B; Sinilnikova O; ; Gentry-Maharaj A; Godwin AK; Goode EL; Goodman MT; Gross J; Hansen TV; Harnett P; Rookus M; ; Heikkinen T; Hein R; Høgdall C; Høgdall E; Iversen ES; Jakubowska A; Johnatty SE; Karlan BY; Kauff ND; Kaye SB; Chenevix-Trench G; ; Kelemen LE; Kiemeney LA; Kjaer SK; Lambrechts D; Lapolla JP; Lázaro C; Le ND; Leminen A; Leunen K; Levine DA; Lu Y; Lundvall L; Macgregor S; Marees T; Massuger LF; McLaughlin JR; Menon U; Montagna M; Moysich KB; Narod SA; Nathanson KL; Nedergaard L; Ness RB; Nevanlinna H; Nickels S; Osorio A; Paul J; Pearce CL; Phelan CM; Pike MC; Radice P; Rossing MA; Schildkraut JM; Sellers TA; Singer CF; Song H; Stram DO; Sutphen R; Lindblom A; ; Terry KL; Tsai YY; van Altena AM; Vergote I; Vierkant RA; Vitonis AF; Walsh C; Wang-Gohrke S; Wappenschmidt B; Wu AH; Ziogas A; Berchuck A; Risch HA;
Clin Cancer Res; 2011 Jun; 17(11):3742-50. PubMed ID: 21385923
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB
Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756
[TBL] [Abstract][Full Text] [Related]
4. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Couch FJ; Gaudet MM; Antoniou AC; Ramus SJ; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; Wang X; Kirchhoff T; McGuffog L; Barrowdale D; Lee A; Healey S; Sinilnikova OM; Andrulis IL; ; Ozcelik H; Mulligan AM; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Caligo MA; von Wachenfeldt A; Barbany-Bustinza G; Loman N; Soller M; Ehrencrona H; Karlsson P; ; Nathanson KL; Rebbeck TR; Domchek SM; Jakubowska A; Lubinski J; Jaworska K; Durda K; Zlowocka E; Huzarski T; Byrski T; Gronwald J; Cybulski C; Górski B; Osorio A; Durán M; Tejada MI; Benitez J; Hamann U; Hogervorst FB; ; van Os TA; van Leeuwen FE; Meijers-Heijboer HE; Wijnen J; Blok MJ; Kets M; Hooning MJ; Oldenburg RA; Ausems MG; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Jacobs C; Eeles RA; Adlard J; Davidson R; Eccles DM; Cole T; Cook J; Paterson J; Brewer C; Douglas F; Hodgson SV; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Side LE; ; Bove B; Godwin AK; Stoppa-Lyonnet D; ; Fassy-Colcombet M; Castera L; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Bressac-de Paillerets B; Caron O; Pujol P; Coupier I; Delnatte C; Akloul L; Lynch HT; Snyder CL; Buys SS; Daly MB; Terry M; Chung WK; John EM; Miron A; Southey MC; Hopper JL; Goldgar DE; Singer CF; Rappaport C; Tea MK; Fink-Retter A; Hansen TV; Nielsen FC; Arason A; Vijai J; Shah S; Sarrel K; Robson ME; Piedmonte M; Phillips K; Basil J; Rubinstein WS; Boggess J; Wakeley K; Ewart-Toland A; Montagna M; Agata S; Imyanitov EN; Isaacs C; Janavicius R; Lazaro C; Blanco I; Feliubadalo L; Brunet J; Gayther SA; Pharoah PP; Odunsi KO; Karlan BY; Walsh CS; Olah E; Teo SH; Ganz PA; Beattie MS; van Rensburg EJ; Dorfling CM; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Heinritz W; Caldes T; de la Hoya M; Muranen TA; Nevanlinna H; Tischkowitz MD; Spurdle AB; Neuhausen SL; Ding YC; Lindor NM; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Bernard L; Viel A; Giannini G; Varesco L; Radice P; Greene MH; Mai PL; Easton DF; Chenevix-Trench G; ; Offit K; Simard J;
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):645-57. PubMed ID: 22351618
[TBL] [Abstract][Full Text] [Related]
5. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
Ding YC; McGuffog L; Healey S; Friedman E; Laitman Y; Paluch-Shimon S; Kaufman B; ; Liljegren A; Lindblom A; Olsson H; Kristoffersson U; Stenmark-Askmalm M; Melin B; Domchek SM; Nathanson KL; Rebbeck TR; Jakubowska A; Lubinski J; Jaworska K; Durda K; Gronwald J; Huzarski T; Cybulski C; Byrski T; Osorio A; Cajal TR; Stavropoulou AV; Benítez J; Hamann U; ; Rookus M; Aalfs CM; de Lange JL; Meijers-Heijboer HE; Oosterwijk JC; van Asperen CJ; Gómez García EB; Hoogerbrugge N; Jager A; van der Luijt RB; ; Easton DF; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Lalloo F; Izatt L; Eeles R; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Godwin AK; Pathak H; ; Stoppa-Lyonnet D; Sinilnikova OM; Mazoyer S; Barjhoux L; Léoné M; Gauthier-Villars M; Caux-Moncoutier V; de Pauw A; Hardouin A; Berthet P; Dreyfus H; Ferrer SF; Collonge-Rame MA; Sokolowska J; Buys S; Daly M; Miron A; Terry MB; Chung W; John EM; Southey M; Goldgar D; Singer CF; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Hansen TV; Ejlertsen B; Johannsson OT; Offit K; Sarrel K; Gaudet MM; Vijai J; Robson M; Piedmonte MR; Andrews L; Cohn D; DeMars LR; DiSilvestro P; Rodriguez G; Toland AE; Montagna M; Agata S; Imyanitov E; Isaacs C; Janavicius R; Lazaro C; Blanco I; Ramus SJ; Sucheston L; Karlan BY; Gross J; Ganz PA; Beattie MS; Schmutzler RK; Wappenschmidt B; Meindl A; Arnold N; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Nevanlinna H; Aittomäki K; Simard J; ; Spurdle AB; Beesley J; Chen X; Tomlinson GE; Weitzel J; Garber JE; Olopade OI; Rubinstein WS; Tung N; Blum JL; Narod SA; Brummel S; Gillen DL; Lindor N; Fredericksen Z; Pankratz VS; Couch FJ; Radice P; Peterlongo P; Greene MH; Loud JT; Mai PL; Andrulis IL; Glendon G; Ozcelik H; ; Gerdes AM; Thomassen M; Jensen UB; Skytte AB; Caligo MA; Lee A; Chenevix-Trench G; Antoniou AC; Neuhausen SL;
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1362-70. PubMed ID: 22729394
[TBL] [Abstract][Full Text] [Related]
6. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Engel C; Versmold B; Wappenschmidt B; Simard J; Easton DF; Peock S; Cook M; Oliver C; Frost D; Mayes R; Evans DG; Eeles R; Paterson J; Brewer C; ; McGuffog L; Antoniou AC; Stoppa-Lyonnet D; Sinilnikova OM; Barjhoux L; Frenay M; Michel C; Leroux D; Dreyfus H; Toulas C; Gladieff L; Uhrhammer N; Bignon YJ; Meindl A; Arnold N; Varon-Mateeva R; Niederacher D; Preisler-Adams S; Kast K; Deissler H; Sutter C; Gadzicki D; Chenevix-Trench G; Spurdle AB; Chen X; Beesley J; ; Olsson H; Kristoffersson U; Ehrencrona H; Liljegren A; ; van der Luijt RB; van Os TA; van Leeuwen FE; ; Domchek SM; Rebbeck TR; Nathanson KL; Osorio A; Ramón y Cajal T; Konstantopoulou I; Benítez J; Friedman E; Kaufman B; Laitman Y; Mai PL; Greene MH; Nevanlinna H; Aittomäki K; Szabo CI; Caldes T; Couch FJ; Andrulis IL; Godwin AK; Hamann U; Schmutzler RK;
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2859-68. PubMed ID: 20978178
[TBL] [Abstract][Full Text] [Related]
7. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract][Full Text] [Related]
8. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Laitman Y; Kuchenbaecker KB; Rantala J; Hogervorst F; Peock S; Godwin AK; Arason A; Kirchhoff T; Offit K; Isaacs C; Schmutzler RK; Wappenschmidt B; Nevanlinna H; Chen X; Chenevix-Trench G; Healey S; Couch F; Peterlongo P; Radice P; Nathanson KL; Caligo MA; Neuhausen SL; Ganz P; Sinilnikova OM; McGuffog L; Easton DF; Antoniou AC; Wolf I; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(3):1119-26. PubMed ID: 22212556
[TBL] [Abstract][Full Text] [Related]
9. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.
Pilarski R; Patel DA; Weitzel J; McVeigh T; Dorairaj JJ; Heneghan HM; Miller N; Weidhaas JB; Kerin MJ; McKenna M; Wu X; Hildebrandt M; Zelterman D; Sand S; Shulman LP
PLoS One; 2012; 7(5):e37891. PubMed ID: 22662244
[TBL] [Abstract][Full Text] [Related]
10. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
11. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
12. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
[TBL] [Abstract][Full Text] [Related]
13. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
14. Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.
Jakubowska A; Rozkrut D; Antoniou A; Hamann U; Scott RJ; McGuffog L; Healy S; Sinilnikova OM; Rennert G; Lejbkowicz F; Flugelman A; Andrulis IL; Glendon G; Ozcelik H; ; Thomassen M; Paligo M; Aretini P; ; Kantala J; Aroer B; von Wachenfeldt A; Liljegren A; Loman N; Herbst K; Kristoffersson U; Rosenquist R; Karlsson P; Stenmark-Askmalm M; Melin B; Nathanson KL; Domchek SM; Byrski T; Huzarski T; Gronwald J; Menkiszak J; Cybulski C; Serrano P; Osorio A; Cajal TR; Tsitlaidou M; Benítez J; Gilbert M; ; Rookus M; Aalfs CM; Kluijt I; Boessenkool-Pape JL; Meijers-Heijboer HE; Oosterwijk JC; van Asperen CJ; Blok MJ; Nelen MR; van den Ouweland AM; Seynaeve C; van der Luijt RB; Devilee P; ; Easton DF; Peock S; Frost D; Platte R; Ellis SD; Fineberg E; Evans DG; Lalloo F; Eeles R; Jacobs C; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Godwin A; Bove B; ; Stoppa-Lyonnet D; Caux-Moncoutier V; Belotti M; Tirapo C; Mazoyer S; Barjhoux L; Boutry-Kryza N; Pujol P; Coupier I; Peyrat JP; Vennin P; Muller D; Fricker JP; Venat-Bouvet L; Johannsson OT; Isaacs C; Schmutzler R; Wappenschmidt B; Meindl A; Arnold N; Varon-Mateeva R; Niederacher D; Sutter C; Deissler H; Preisler-Adams S; Simard J; Soucy P; Durocher F; Chenevix-Trench G; Beesley J; Chen X; ; Rebbeck T; Couch F; Wang X; Lindor N; Fredericksen Z; Pankratz VS; Peterlongo P; Bonanni B; Fortuzzi S; Peissel B; Szabo C; Mai PL; Loud JT; Lubinski J;
Br J Cancer; 2012 Jun; 106(12):2016-24. PubMed ID: 22669161
[TBL] [Abstract][Full Text] [Related]
15. The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.
Jakubowska A; Rozkrut D; Antoniou A; Hamann U; Lubinski J
Breast Cancer Res Treat; 2010 Jun; 121(3):639-49. PubMed ID: 19876733
[TBL] [Abstract][Full Text] [Related]
16. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
17. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
[TBL] [Abstract][Full Text] [Related]
19. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
Speight B; Tischkowitz M
J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
[TBL] [Abstract][Full Text] [Related]
20. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
